Middle East & Africa Peptide Therapeutics Market Size & Outlook
Middle East & Africa peptide therapeutics market, 2018-2030 (US$M)
Related Markets
MEA peptide therapeutics market highlights
- The MEA peptide therapeutics market generated a revenue of USD 2,167.9 million in 2023.
- The market is expected to grow at a CAGR of 10.9% from 2024 to 2030.
- In terms of segment, metabolic disorders was the largest revenue generating application in 2023.
- Metabolic disorders is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Kuwait is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 2,167.9 million |
| Market revenue in 2030 | USD 4,462.4 million |
| Growth rate | 10.9% (CAGR from 2023 to 2030) |
| Largest segment | Metabolic disorders |
| Fastest growing segment | Metabolic disorders |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cancer, Metabolic disorders, Cardiovascular disorders, Respiratory disorders, Gastrointestinal disorders, Infectious disease, Pain, Dermatological disorders, Neurological disorders, Renal disorders |
| Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Amgen Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, Sanofi SA, Roche Holding AG, Novartis AG ADR, Novo Nordisk A/S ADR, GlaxoSmithKline, Ironwood Pharmaceuticals Inc Class A, Ipsen SA, Radius Health |
Other key industry trends
- In terms of revenue, MEA region accounted for 2.3% of the global peptide therapeutics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 172,089.8 million by 2030.
Metabolic disorders was the largest segment with a revenue share of 59.38% in 2023. Horizon Databook has segmented the Middle East & Africa peptide therapeutics market based on cancer, metabolic disorders, cardiovascular disorders, respiratory disorders, gastrointestinal disorders, infectious disease, pain, dermatological disorders, neurological disorders, renal disorders covering the revenue growth of each sub-segment from 2018 to 2030.
Major markets in the MEA region include South Africa, Saudi Arabia, the UAE, and Kuwait. Economic development witnessed in emerging markets like South Africa, high unmet healthcare needs, and the significant prevalence of target diseases are some primary drivers of the market.
In addition, an increase in government initiatives and a rise in partnerships of key players with healthcare providers are anticipated to boost the market over the forecast period. Furthermore, the increased death rate due to these target diseases is driving the need for the development of effective therapeutics to prevent such conditions.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Peptide Therapeutics Market Scope
Peptide Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
MEA peptide therapeutics market size, by country, 2018-2030 (US$M)
Middle East & Africa Peptide Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
